Symbols / CRNX
CRNX Chart
About
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.56B |
| Enterprise Value | 3.18B | Income | -423.10M | Sales | 1.53M |
| Book/sh | 11.34 | Cash/sh | 11.51 | Dividend Yield | — |
| Payout | 0.00% | Employees | 437 | IPO | — |
| P/E | — | Forward P/E | -8.96 | PEG | — |
| P/S | 2973.18 | P/B | 3.93 | P/C | — |
| EV/EBITDA | -6.71 | EV/Sales | 2072.60 | Quick Ratio | 14.73 |
| Current Ratio | 15.12 | Debt/Eq | 4.58 | LT Debt/Eq | — |
| EPS (ttm) | -4.60 | EPS next Y | -4.97 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-26 | ROA | -28.00% |
| ROE | -44.42% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -997.10% | Profit Margin | 0.00% | Shs Outstand | 102.51M |
| Shs Float | 87.13M | Short Float | 15.72% | Short Ratio | 9.57 |
| Short Interest | — | 52W High | 57.99 | 52W Low | 24.10 |
| Beta | 0.19 | Avg Volume | 1.20M | Volume | 609.17K |
| Target Price | $85.00 | Recom | Strong_buy | Prev Close | $43.79 |
| Price | $44.52 | Change | 1.67% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$85.00
Mean price target
2. Current target
$44.52
Latest analyst target
3. DCF / Fair value
$-36.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$44.52
Low
$55.00
High
$105.00
Mean
$85.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-12 | up | Goldman Sachs | Neutral → Buy | $67 |
| 2026-01-08 | main | Citizens | Market Outperform → Market Outperform | $105 |
| 2026-01-06 | main | Morgan Stanley | Overweight → Overweight | $80 |
| 2025-11-07 | main | Citizens | Market Outperform → Market Outperform | $108 |
| 2025-09-30 | main | Oppenheimer | Outperform → Outperform | $87 |
| 2025-09-29 | main | Morgan Stanley | Overweight → Overweight | $77 |
| 2025-09-29 | main | Leerink Partners | Outperform → Outperform | $88 |
| 2025-09-26 | main | Goldman Sachs | Neutral → Neutral | $40 |
| 2025-09-26 | main | JMP Securities | Market Outperform → Market Outperform | $143 |
| 2025-09-26 | main | Baird | Outperform → Outperform | $62 |
| 2025-09-24 | main | JP Morgan | Overweight → Overweight | $52 |
| 2025-08-11 | main | JMP Securities | Market Outperform → Market Outperform | $86 |
| 2025-06-27 | reit | HC Wainwright & Co. | Buy → Buy | $81 |
| 2025-03-25 | init | Stifel | — → Buy | $60 |
| 2025-02-28 | main | Citizens Capital Markets | Market Outperform → Market Outperform | $91 |
| 2025-02-04 | init | Wolfe Research | — → Peer Perform | — |
| 2025-01-22 | up | Jefferies | Hold → Buy | $55 |
| 2025-01-13 | reit | HC Wainwright & Co. | Buy → Buy | $81 |
| 2024-12-16 | reit | JMP Securities | Market Outperform → Market Outperform | $87 |
| 2024-11-14 | main | Citigroup | Buy → Buy | $74 |
- How Positive CAH Phase 2 Data And Palsonify Uptake At Crinetics Pharmaceuticals (CRNX) Has Changed Its Investment Story - simplywall.st Mon, 23 Feb 2026 04
- Analysts Bullish on Crinetics (CRNX) Amid Positive Clinical Trial for New Drug - Yahoo Finance hu, 19 Feb 2026 00
- Crinetics plans March appearances at TD Cowen and Leerink events - Stock Titan hu, 05 Feb 2026 08
- $CRNX stock is down 8% today. Here's what we see in our data. - Quiver Quantitative hu, 18 Dec 2025 08
- Interesting CRNX Put And Call Options For November 21st - Nasdaq Fri, 19 Sep 2025 07
- Liquidity Mapping Around (CRNX) Price Events - Stock Traders Daily Fri, 06 Feb 2026 08
- Candriam S.C.A. Grows Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat ue, 10 Feb 2026 08
- Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral - Yahoo Finance hu, 15 Jan 2026 08
- 10 new Crinetics workers get stock awards vesting over 4 years - Stock Titan Mon, 12 Jan 2026 08
- Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility - Yahoo Finance Mon, 26 Jan 2026 08
- Is It Too Late To Consider Crinetics Pharmaceuticals (CRNX) After Strong Multi‑Year Share Gains? - simplywall.st hu, 22 Jan 2026 08
- Drugmaker seeks $350M to launch PALSONIFY and fund new therapies - Stock Titan Mon, 05 Jan 2026 08
- Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance hu, 06 Nov 2025 08
- Crinetics Pharmaceuticals (CRNX): Valuation in Focus After FDA Approval and Positive PALSONIFY Launch Momentum - Yahoo Finance Sun, 09 Nov 2025 08
- Those who invested in Crinetics Pharmaceuticals (NASDAQ:CRNX) five years ago are up 151% - Yahoo Finance hu, 18 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2500 | 137500 | — | Sale at price 55.00 per share. | KALOFONOS ISABEL | Officer | — | 2026-01-05 00:00:00 | D |
| 1 | 2500 | 101475 | — | Conversion of Exercise of derivative security at price 40.59 per share. | KALOFONOS ISABEL | Officer | — | 2026-01-05 00:00:00 | D |
| 2 | 18000 | 34380 | — | Conversion of Exercise of derivative security at price 1.91 per share. | BETZ STEPHEN F | Officer | — | 2025-12-26 00:00:00 | D |
| 3 | 44742 | 585890 | — | Conversion of Exercise of derivative security at price 9.28 - 15.29 per share. | STRUTHERS RICHARD SCOTT | Chief Executive Officer | — | 2025-12-18 00:00:00 | D |
| 4 | 5000 | 225100 | — | Sale at price 45.02 per share. | PIZZUTI DANA J | Officer | — | 2025-12-01 00:00:00 | D |
| 5 | 5000 | 84450 | — | Conversion of Exercise of derivative security at price 16.89 per share. | PIZZUTI DANA J | Officer | — | 2025-12-01 00:00:00 | D |
| 6 | 5000 | 213312 | — | Sale at price 42.65 - 43.27 per share. | PIZZUTI DANA J | Officer | — | 2025-11-03 00:00:00 | D |
| 7 | 5000 | 84450 | — | Conversion of Exercise of derivative security at price 16.89 per share. | PIZZUTI DANA J | Officer | — | 2025-11-03 00:00:00 | D |
| 8 | 5000 | 209050 | — | Sale at price 41.81 per share. | PIZZUTI DANA J | Officer | — | 2025-10-01 00:00:00 | D |
| 9 | 5000 | 84450 | — | Conversion of Exercise of derivative security at price 16.89 per share. | PIZZUTI DANA J | Officer | — | 2025-10-01 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -336.07M | -221.51M | -167.50M | -106.78M |
| TotalUnusualItems | 600.00K | |||
| TotalUnusualItemsExcludingGoodwill | 600.00K | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -298.41M | -214.53M | -163.92M | -107.64M |
| ReconciledDepreciation | 2.79M | 1.10M | 983.00K | 922.00K |
| EBITDA | -336.07M | -221.51M | -166.90M | -106.78M |
| EBIT | -338.85M | -222.61M | -167.88M | -107.70M |
| NetInterestIncome | 41.44M | 13.44M | 4.32M | 157.00K |
| InterestIncome | 41.44M | 13.44M | 4.32M | 157.00K |
| NormalizedIncome | -298.41M | -214.53M | -164.52M | -107.64M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -298.41M | -214.53M | -163.92M | -107.64M |
| TotalExpenses | 339.89M | 226.62M | 172.62M | 108.78M |
| TotalOperatingIncomeAsReported | -338.85M | -222.61M | -167.88M | -107.70M |
| DilutedAverageShares | 80.78M | 58.07M | 51.98M | 38.44M |
| BasicAverageShares | 80.78M | 58.07M | 51.98M | 38.44M |
| DilutedEPS | -3.69 | -3.69 | -3.15 | -2.80 |
| BasicEPS | -3.69 | -3.69 | -3.15 | -2.80 |
| DilutedNIAvailtoComStockholders | -298.41M | -214.53M | -163.92M | -107.64M |
| NetIncomeCommonStockholders | -298.41M | -214.53M | -163.92M | -107.64M |
| NetIncome | -298.41M | -214.53M | -163.92M | -107.64M |
| NetIncomeIncludingNoncontrollingInterests | -298.41M | -214.53M | -163.92M | -107.64M |
| NetIncomeContinuousOperations | -298.41M | -214.53M | -163.92M | -107.64M |
| PretaxIncome | -298.41M | -214.53M | -163.92M | -107.64M |
| OtherIncomeExpense | -989.00K | -5.36M | -353.00K | -96.00K |
| OtherNonOperatingIncomeExpenses | -519.00K | -159.00K | 57.00K | -96.00K |
| EarningsFromEquityInterest | -470.00K | -5.20M | -1.01M | 0.00 |
| GainOnSaleOfSecurity | 600.00K | |||
| NetNonOperatingInterestIncomeExpense | 41.44M | 13.44M | 4.32M | 157.00K |
| InterestIncomeNonOperating | 41.44M | 13.44M | 4.32M | 157.00K |
| OperatingIncome | -338.85M | -222.61M | -167.88M | -107.70M |
| OperatingExpense | 339.89M | 226.62M | 172.62M | 108.78M |
| ResearchAndDevelopment | 240.16M | 168.53M | 130.22M | 84.25M |
| SellingGeneralAndAdministration | 99.74M | 58.09M | 42.39M | 24.52M |
| GeneralAndAdministrativeExpense | 99.74M | 58.09M | 42.39M | 24.52M |
| OtherGandA | 99.74M | 58.09M | 42.39M | 24.52M |
| TotalRevenue | 1.04M | 4.01M | 4.74M | 1.08M |
| OperatingRevenue | 1.04M | 4.01M | 4.74M | 1.08M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 92.93M | 68.17M | 53.88M | 47.60M |
| ShareIssued | 92.93M | 68.17M | 53.88M | 47.60M |
| TotalDebt | 51.72M | 51.73M | 3.08M | 3.07M |
| TangibleBookValue | 1.32B | 539.11M | 316.33M | 331.94M |
| InvestedCapital | 1.32B | 539.11M | 316.33M | 331.94M |
| WorkingCapital | 1.32B | 530.21M | 317.46M | 328.73M |
| NetTangibleAssets | 1.32B | 539.11M | 316.33M | 331.94M |
| CapitalLeaseObligations | 51.72M | 51.73M | 3.08M | 3.07M |
| CommonStockEquity | 1.32B | 539.11M | 316.33M | 331.94M |
| TotalCapitalization | 1.32B | 539.11M | 316.33M | 331.94M |
| TotalEquityGrossMinorityInterest | 1.32B | 539.11M | 316.33M | 331.94M |
| StockholdersEquity | 1.32B | 539.11M | 316.33M | 331.94M |
| GainsLossesNotAffectingRetainedEarnings | 963.00K | 977.00K | -3.93M | -382.00K |
| OtherEquityAdjustments | 963.00K | 977.00K | -3.93M | -382.00K |
| RetainedEarnings | -952.11M | -653.70M | -439.17M | -275.25M |
| CapitalStock | 2.28B | 1.19B | 759.43M | 607.58M |
| CommonStock | 2.28B | 1.19B | 759.43M | 607.58M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 109.79M | 96.25M | 35.85M | 19.07M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 50.10M | 52.30M | 8.12M | 3.08M |
| OtherNonCurrentLiabilities | 829.00K | 2.00K | ||
| RestrictedCommonStock | 2.00K | |||
| NonCurrentDeferredLiabilities | 4.70M | 4.75M | 6.10M | 0.00 |
| NonCurrentDeferredRevenue | 4.70M | 4.75M | 6.10M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 44.57M | 47.55M | 2.02M | 3.07M |
| LongTermCapitalLeaseObligation | 44.57M | 47.55M | 2.02M | 3.07M |
| CurrentLiabilities | 59.68M | 43.94M | 27.72M | 15.99M |
| OtherCurrentLiabilities | 1.05M | 939.00K | ||
| CurrentDeferredLiabilities | 2.18M | 2.06M | 2.24M | 0.00 |
| CurrentDeferredRevenue | 2.18M | 2.06M | 2.24M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 7.15M | 4.17M | 1.05M | |
| CurrentCapitalLeaseObligation | 7.15M | 4.17M | 1.05M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 28.89M | 14.52M | 9.08M | 6.59M |
| PayablesAndAccruedExpenses | 21.47M | 23.20M | 15.35M | 8.47M |
| CurrentAccruedExpenses | 15.62M | 16.65M | 8.47M | 5.05M |
| Payables | 5.85M | 6.55M | 6.88M | 3.42M |
| AccountsPayable | 5.85M | 6.55M | 6.88M | 3.42M |
| TotalAssets | 1.43B | 635.35M | 352.18M | 351.01M |
| TotalNonCurrentAssets | 59.20M | 61.20M | 6.99M | 6.29M |
| OtherNonCurrentAssets | 3.63M | 3.30M | 1.34M | 500.00K |
| FinancialAssets | 0.00 | 668.00K | 68.00K | |
| InvestmentsAndAdvances | 0.00 | 470.00K | 0.00 | 1.01M |
| LongTermEquityInvestment | 0.00 | 470.00K | 0.00 | 1.01M |
| InvestmentsinSubsidiariesatCost | 0.00 | 470.00K | 0.00 | 1.01M |
| NetPPE | 55.58M | 57.43M | 4.99M | 4.72M |
| AccumulatedDepreciation | -7.73M | -5.07M | -4.08M | -3.48M |
| GrossPPE | 63.31M | 62.50M | 9.07M | 8.20M |
| Leases | 11.90M | 9.84M | 3.52M | 3.52M |
| OtherProperties | 49.20M | 50.80M | 4.65M | 3.78M |
| MachineryFurnitureEquipment | 2.21M | 1.86M | 900.00K | 900.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.38B | 574.15M | 345.18M | 344.72M |
| OtherCurrentAssets | 1.21M | 448.00K | 1.93M | 912.00K |
| RestrictedCash | 500.00K | 0.00 | ||
| PrepaidAssets | 11.14M | 5.80M | 5.80M | 8.98M |
| Receivables | 8.47M | 9.35M | 3.03M | 2.03M |
| OtherReceivables | 86.00K | 5.46M | 605.00K | |
| DuefromRelatedPartiesCurrent | 0.00 | 90.00K | 135.00K | 553.00K |
| TaxesReceivable | 74.00K | 747.00K | 937.00K | 977.00K |
| AccruedInterestReceivable | 8.31M | 3.05M | 1.35M | 499.00K |
| CashCashEquivalentsAndShortTermInvestments | 1.35B | 558.55M | 334.43M | 333.71M |
| OtherShortTermInvestments | 1.09B | 503.66M | 301.75M | 133.01M |
| CashAndCashEquivalents | 264.55M | 54.90M | 32.67M | 200.69M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -229.81M | -171.00M | -116.86M | -89.02M |
| RepurchaseOfCapitalStock | 0.00 | |||
| IssuanceOfCapitalStock | 970.05M | 369.02M | 117.24M | 249.54M |
| CapitalExpenditure | -3.84M | -4.69M | -1.66M | -436.00K |
| EndCashPosition | 265.85M | 56.20M | 33.97M | 201.19M |
| BeginningCashPosition | 56.20M | 33.97M | 201.19M | 93.59M |
| ChangesInCash | 209.65M | 22.22M | -167.22M | 107.61M |
| FinancingCashFlow | 1.01B | 388.94M | 121.96M | 252.68M |
| CashFlowFromContinuingFinancingActivities | 1.01B | 388.94M | 121.96M | 252.68M |
| ProceedsFromStockOptionExercised | 40.39M | 19.93M | 4.72M | 3.14M |
| NetCommonStockIssuance | 970.05M | 369.02M | 117.24M | 249.54M |
| CommonStockPayments | 0.00 | |||
| CommonStockIssuance | 970.05M | 369.02M | 117.24M | 249.54M |
| InvestingCashFlow | -574.82M | -200.41M | -173.98M | -56.48M |
| CashFlowFromContinuingInvestingActivities | -574.82M | -200.41M | -173.98M | -56.48M |
| NetInvestmentPurchaseAndSale | -570.97M | -195.72M | -172.32M | -56.05M |
| SaleOfInvestment | 575.80M | 337.13M | 157.49M | 69.36M |
| PurchaseOfInvestment | -1.15B | -532.86M | -329.82M | -125.40M |
| NetPPEPurchaseAndSale | -3.84M | -4.69M | -1.66M | -436.00K |
| PurchaseOfPPE | -3.84M | -4.69M | -1.66M | -436.00K |
| OperatingCashFlow | -225.97M | -166.31M | -115.20M | -88.59M |
| CashFlowFromContinuingOperatingActivities | -225.97M | -166.31M | -115.20M | -88.59M |
| ChangeInWorkingCapital | 11.63M | 8.04M | 18.61M | 1.10M |
| ChangeInOtherWorkingCapital | 74.00K | -1.53M | 8.34M | |
| ChangeInOtherCurrentLiabilities | -6.00K | -546.00K | -938.00K | -836.00K |
| ChangeInPayablesAndAccruedExpense | 6.29M | |||
| ChangeInPayable | 6.29M | |||
| ChangeInAccountPayable | 6.29M | |||
| ChangeInPrepaidAssets | -5.97M | -4.52M | 215.00K | -4.36M |
| ChangeInReceivables | 17.54M | 14.65M | 10.99M | 6.29M |
| ChangesInAccountReceivables | 17.54M | 14.65M | 10.99M | 6.29M |
| OtherNonCashItems | 3.04M | -790.00K | 406.00K | -739.00K |
| StockBasedCompensation | 69.39M | 40.94M | 28.27M | 17.35M |
| AmortizationOfSecurities | -14.93M | -6.27M | 34.00K | 422.00K |
| DepreciationAmortizationDepletion | 2.79M | 1.10M | 983.00K | 922.00K |
| DepreciationAndAmortization | 2.79M | 1.10M | 983.00K | 922.00K |
| OperatingGainsLosses | 521.00K | 5.20M | 410.00K | |
| EarningsLossesFromEquityInvestments | 470.00K | 5.20M | 1.01M | 0.00 |
| GainLossOnInvestmentSecurities | -600.00K | |||
| GainLossOnSaleOfPPE | 51.00K | 6.00K | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -298.41M | -214.53M | -163.92M | -107.64M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CRNX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|